Time course of sFGL2 levels in two patients with chronic HCV infection treated with anti-viral therapy. A) Patient 1 with genotype 1 infection did not respond to 48 weeks of therapy with pegylated interferon and Ribavirin. Plasma sFGL2 levels in this patient were high prior to initiation of therapy, throughout treatment and 6 months after completion of therapy. B) Patient 2 with genotype 2 infection responded to anti-viral therapy. Plasma levels of sFGL2 were low prior to initiation of treatment and fell within 4 weeks of therapy to levels similar to healthy controls and remained very low after completion of therapy.